A systematic review on the effect of bevacizumab in exudative age-related macular degeneration

被引:0
作者
Christine Schmucker
Gerd Antes
Monika Lelgemann
机构
[1] University Medical Centre Freiburg,German Cochrane Centre
[2] University Bremen,Health Technology Assessment Centre
来源
Graefe's Archive for Clinical and Experimental Ophthalmology | 2010年 / 248卷
关键词
Age-related macular degeneration; Bevacizumab; Efficacy; Safety;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:451 / 452
页数:1
相关论文
共 41 条
[1]  
Bashshur ZF(2007)Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration Arch Ophthalmol 125 1357-1361
[2]  
Schakal A(2009)Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57-69
[3]  
Hamam RN(2007)Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 245 68-73
[4]  
El Haibi CP(2007)Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macular degenereation Ophthalmologe 104 588-593
[5]  
Jaafar RF(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[6]  
Noureddin B(2008)Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 81-87
[7]  
Brown DM(2006)The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide Br J Ophthalmol 90 1344-1349
[8]  
Michels M(undefined)undefined undefined undefined undefined-undefined
[9]  
Kaiser PK(undefined)undefined undefined undefined undefined-undefined
[10]  
Heier JS(undefined)undefined undefined undefined undefined-undefined